Pharmaceutical Executive January 7, 2026
When approaching cell and gene therapies (CGT), investors want to back companies that demonstrate operational foresight. Here are five levers for building a CGT operating model that can tackle the category’s unique commercialization complexities.
The past two years have tested the cell and gene therapy (CGT) space. While Vertex’s Casgevy approval at a fraction of its potential, even as major investments poured in from AbbVie, Eli Lilly, and AstraZeneca.
There is confidence in the science but uncertainty about who can navigate CGT’s unique complexities: small patient populations, high payer switching rates, uncertain long-term outcomes, and supply chains built around patient-specific doses and delivery.
In this article, I discuss five strategic levers that biotechs can use to tackle this complexity. These...
Today's Sponsors
Today's Sponsor